Skip to main content
PMC home page
Transactions of the American Clinical and Climatological Association logoLink to Transactions of the American Clinical and Climatological Association
. 2002;113:31–41.

Hormones and heart disease: what we thought, what we have learned, what we still need to know.

Marian C Limacher 1
PMCID: PMC2194486  PMID: 12053716

Abstract

Hormone replacement therapy has previously been recommended for the prevention and treatment of many conditions affecting women as they age. Decades of research have determined many beneficial biologic effects of hormones on the direct and indirect mechanisms of atherosclerosis. Observational studies have furthered the enthusiasm for hormone use with estimates of 35-50% reduction in risk for future cardiovascular events in women who took estrogens at menopause. However, there may be inherent selection and compliance biases in the non-randomized cohort methodology. The last decade has produced important randomized clinical trial results which now question whether estrogen replacement will reduce risks or even potentially increase cardiovascular event rates, particularly in women with known coronary disease within the first 1-2 years of initiating treatment. Conclusive evidence of the true risk:benefit ratio for hormone use after menopause awaits the completion of ongoing clinical trials. Until those results are available, each decision for postmenopausal hormone use must be made on a case-by-case basis weighing individual risks with the positive and negative aspects of therapy.

Full text

PDF
32

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams M. R., Kaplan J. R., Manuck S. B., Koritnik D. R., Parks J. S., Wolfe M. S., Clarkson T. B. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990 Nov-Dec;10(6):1051–1057. doi: 10.1161/01.atv.10.6.1051. [DOI] [PubMed] [Google Scholar]
  2. Adams M. R., Register T. C., Golden D. L., Wagner J. D., Williams J. K. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997 Jan;17(1):217–221. doi: 10.1161/01.atv.17.1.217. [DOI] [PubMed] [Google Scholar]
  3. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991 Sep 15;115(6):455–456. doi: 10.7326/0003-4819-115-6-455. [DOI] [PubMed] [Google Scholar]
  4. Bush D. E., Jones C. E., Bass K. M., Walters G. K., Bruza J. M., Ouyang P. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med. 1998 Jun;104(6):552–558. doi: 10.1016/s0002-9343(98)00117-x. [DOI] [PubMed] [Google Scholar]
  5. Bush T. L. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J. 1996 Aug;17 (Suppl 500):9–14. doi: 10.1093/eurheartj/17.suppl_d.9. [DOI] [PubMed] [Google Scholar]
  6. Cohen Y., Raz I., Merin G., Mozes B. Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Am J Cardiol. 1998 Jan 1;81(1):7–11. doi: 10.1016/s0002-9149(97)00797-2. [DOI] [PubMed] [Google Scholar]
  7. Cushman M., Legault C., Barrett-Connor E., Stefanick M. L., Kessler C., Judd H. L., Sakkinen P. A., Tracy R. P. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999 Aug 17;100(7):717–722. doi: 10.1161/01.cir.100.7.717. [DOI] [PubMed] [Google Scholar]
  8. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995 Jan 18;273(3):199–208. [PubMed] [Google Scholar]
  9. Espeland M. A., Applegate W., Furberg C. D., Lefkowitz D., Rice L., Hunninghake D. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol. 1995 Nov 15;142(10):1011–1019. doi: 10.1093/oxfordjournals.aje.a117553. [DOI] [PubMed] [Google Scholar]
  10. Espeland M. A., Marcovina S. M., Miller V., Wood P. D., Wasilauskas C., Sherwin R., Schrott H., Bush T. L. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation. 1998 Mar 17;97(10):979–986. doi: 10.1161/01.cir.97.10.979. [DOI] [PubMed] [Google Scholar]
  11. Gerhard M., Walsh B. W., Tawakol A., Haley E. A., Creager S. J., Seely E. W., Ganz P., Creager M. A. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 1998 Sep 22;98(12):1158–1163. doi: 10.1161/01.cir.98.12.1158. [DOI] [PubMed] [Google Scholar]
  12. Haines C., Chung T., Chang A., Masarei J., Tomlinson B., Wong E. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study. Arch Intern Med. 1996 Apr 22;156(8):866–872. [PubMed] [Google Scholar]
  13. Herrington D. M., Reboussin D. M., Brosnihan K. B., Sharp P. C., Shumaker S. A., Snyder T. E., Furberg C. D., Kowalchuk G. J., Stuckey T. D., Rogers W. J. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000 Aug 24;343(8):522–529. doi: 10.1056/NEJM200008243430801. [DOI] [PubMed] [Google Scholar]
  14. Hough J. L., Zilversmit D. B. Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits. Arteriosclerosis. 1986 Jan-Feb;6(1):57–63. doi: 10.1161/01.atv.6.1.57. [DOI] [PubMed] [Google Scholar]
  15. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19;280(7):605–613. doi: 10.1001/jama.280.7.605. [DOI] [PubMed] [Google Scholar]
  16. Lobo R. A., Notelovitz M., Bernstein L., Khan F. Y., Ross R. K., Paul W. L. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen. Am J Obstet Gynecol. 1992 Apr;166(4):1182–1190. [PubMed] [Google Scholar]
  17. Lobo R. A., Pickar J. H., Wild R. A., Walsh B., Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol. 1994 Dec;84(6):987–995. [PubMed] [Google Scholar]
  18. Manolio T. A., Pearson T. A., Wenger N. K., Barrett-Connor E., Payne G. H., Harlan W. R. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol. 1992 Jan-Mar;2(1-2):161–176. doi: 10.1016/1047-2797(92)90051-q. [DOI] [PubMed] [Google Scholar]
  19. Matthews K. A., Kuller L. H., Wing R. R., Meilahn E. N., Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996 May 15;143(10):971–978. doi: 10.1093/oxfordjournals.aje.a008678. [DOI] [PubMed] [Google Scholar]
  20. Mosca L. Estrogen and atherosclerosis. J Investig Med. 1998 Oct;46(8):381–386. [PubMed] [Google Scholar]
  21. Mosca L., Grundy S. M., Judelson D., King K., Limacher M., Oparil S., Pasternak R., Pearson T. A., Redberg R. F., Smith S. C., Jr Guide to Preventive Cardiology for Women.AHA/ACC Scientific Statement Consensus panel statement. Circulation. 1999 May 11;99(18):2480–2484. doi: 10.1161/01.cir.99.18.2480. [DOI] [PubMed] [Google Scholar]
  22. Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med. 2000 Aug 14;160(15):2263–2272. doi: 10.1001/archinte.160.15.2263. [DOI] [PubMed] [Google Scholar]
  23. Mäkilä U. M., Wahlberg L., Vlinikka L., Ylikorkala O. Regulation of prostacyclin and thromboxane production by human umbilical vessels: the effect of estradiol and progesterone in a superfusion model. Prostaglandins Leukot Med. 1982 Feb;8(2):115–124. doi: 10.1016/s0262-1746(82)80003-6. [DOI] [PubMed] [Google Scholar]
  24. O'Sullivan A. J., Crampton L. J., Freund J., Ho K. K. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest. 1998 Sep 1;102(5):1035–1040. doi: 10.1172/JCI2773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. PICK R., STAMLER J., RODBARD S., KATZ L. N. The inhibition of coronary atherosclerosis by estrogens in cholesterol-fed chicks. Circulation. 1952 Aug;6(2):276–280. doi: 10.1161/01.cir.6.2.276. [DOI] [PubMed] [Google Scholar]
  26. Reis S. E., Gloth S. T., Blumenthal R. S., Resar J. R., Zacur H. A., Gerstenblith G., Brinker J. A. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 1994 Jan;89(1):52–60. doi: 10.1161/01.cir.89.1.52. [DOI] [PubMed] [Google Scholar]
  27. Roqué M., Heras M., Roig E., Masotti M., Rigol M., Betriu A., Balasch J., Sanz G. Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. J Am Coll Cardiol. 1998 Jan;31(1):139–143. doi: 10.1016/s0735-1097(97)00436-1. [DOI] [PubMed] [Google Scholar]
  28. Rosenson R. S., Tangney C. C., Mosca L. J. Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women. Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1902–1905. doi: 10.1161/01.atv.18.12.1902. [DOI] [PubMed] [Google Scholar]
  29. Shewmon D. A., Stock J. L., Rosen C. J., Heiniluoma K. M., Hogue M. M., Morrison A., Doyle E. M., Ukena T., Weale V., Baker S. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb. 1994 Oct;14(10):1586–1593. doi: 10.1161/01.atv.14.10.1586. [DOI] [PubMed] [Google Scholar]
  30. Sorensen K. E., Dorup I., Hermann A. P., Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation. 1998 Apr 7;97(13):1234–1238. doi: 10.1161/01.cir.97.13.1234. [DOI] [PubMed] [Google Scholar]
  31. Stampfer M. J., Colditz G. A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991 Jan;20(1):47–63. doi: 10.1016/0091-7435(91)90006-p. [DOI] [PubMed] [Google Scholar]
  32. Sullivan J. M., Vander Zwaag R., Hughes J. P., Maddock V., Kroetz F. W., Ramanathan K. B., Mirvis D. M. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med. 1990 Dec;150(12):2557–2562. [PubMed] [Google Scholar]
  33. WILSON R. A., WILSON T. A. The fate of the nontreated postmenopausal woman: a plea for the maintenance of adequate estrogen from puberty to the grave. J Am Geriatr Soc. 1963 Apr;11:347–362. doi: 10.1111/j.1532-5415.1963.tb00068.x. [DOI] [PubMed] [Google Scholar]
  34. Wakatsuki A., Ikenoue N., Sagara Y. Effects of estrogen on susceptibility to oxidation of low-density and high-density lipoprotein in postmenopausal women. Maturitas. 1998 Jan 12;28(3):229–234. doi: 10.1016/s0378-5122(97)00072-8. [DOI] [PubMed] [Google Scholar]
  35. Walsh B. W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F. M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991 Oct 24;325(17):1196–1204. doi: 10.1056/NEJM199110243251702. [DOI] [PubMed] [Google Scholar]
  36. Williams J. K., Anthony M. S., Honoré E. K., Herrington D. M., Morgan T. M., Register T. C., Clarkson T. B. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 1995 Jul;15(7):827–836. doi: 10.1161/01.atv.15.7.827. [DOI] [PubMed] [Google Scholar]
  37. Zenker G., Költringer P., Boné G., Niederkorn K., Pfeiffer K., Jürgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1986 Sep-Oct;17(5):942–945. doi: 10.1161/01.str.17.5.942. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Clinical and Climatological Association are provided here courtesy of American Clinical and Climatological Association

RESOURCES